Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

6/22/2004 8:26:10 AM ET

SWISS MEDICA RESALE REGISTRATION STATEMENT DECLARED EFFECTIVE

Stock Symbol: OTC BB: SWME

June 21, 2004

SWISS MEDICA RESALE REGISTRATION STATEMENT DECLARED EFFECTIVE

Toronto, Canada - Swiss Medica Inc. (OTCBB: SWME) today announced that the Securities and Exchange

Commission declared the Company’s resale registration statement effective as of June 21, 2004. The resale

registration statement, filed on Form SB-2 (File No. 333-115539), covers 21,577,500 shares of Swiss Medica

Common Stock issued and 30,946,250 shares of Swiss Medica Common Stock underlying warrants issued to

selling stockholders in connection with the Company’s private placement closed on March 31, 2004.

Selling stockholders included in the resale registration statement may obtain a copy of the prospectus relating to

their shares of Swiss Medica Common Stock via email at info@swissmedica.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any

sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration

or qualification under the securities.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be

a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and www.024zone.com.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

David Jones

Swiss Medica Inc.

1 866 485 4243